Shanmuganathan Chandrakasan
Emory University · United States
Editorial leadership for Journal of Bone Marrow Biology
Research interests
- Bone Marrow Transplant Stem Cell Stress Novel Stem Cell Conditioning Approach Immune Deficiency
Biography
Shanmuganathan Chandrakasan is a senior clinical fellow in hematology-oncology, bone marrow transplantation, and immune deficiency at Emory University. His primary research interests focus on novel stem cell conditioning approaches and the role of stem cell survival pathways in transplantation. He also investigates immune barriers to engraftment, contributing to advances in hematopoietic stem cell transplantation outcomes. His most-cited work, "Frequency of HLA-DR+CD38hi T cells identifies and quantifies T-cell activation in hemophagocytic lymphohistiocytosis, hyperinflammation, and immune regulatory disorders" (2024), has received 47 citations and reflects his expertise in immune dysregulation and hyperinflammatory conditions. With over 24 indexed publications, his research addresses critical challenges in transplant immunology and immune deficiency disorders.
Selected publications
- Frequency of HLA-DR+CD38hi T cells identifies and quantifies T-cell activation in hemophagocytic lymphohistiocytosis, hyperinflammation, and immune regulatory disorders 2024 cited 47×
- Distinguishing immune activation and inflammatory signatures of multisystem inflammatory syndrome in children (MIS-C) versus hemophagocytic lymphohistiocytosis (HLH) 2022 cited 41×
- Targeting vasoactive intestinal peptide-mediated signaling enhances response to immune checkpoint therapy in pancreatic ductal adenocarcinoma 2022 cited 38×
- T-follicular helper cell expansion and chronic T-cell activation are characteristic immune anomalies in Evans syndrome 2022 cited 35×
- High risk of relapsed disease in patients with NK/T-cell chronic active Epstein-Barr virus disease outside of Asia 2022 cited 29×
- Antiviral cellular therapy for enhancing T-cell reconstitution before or after hematopoietic stem cell transplantation (ACES): a two-arm, open label phase II interventional trial of pediatric patients with risk factor assessment 2024 cited 26×
Ranked by citation impact (Crossref) where available, newest otherwise · verified via ORCID.
Considering JBMB for your work?
This journal is guided by Shanmuganathan Chandrakasan (Emory University) and a peer-review board of practising researchers. Open access, author-retained copyright (CC BY), and a clear editorial process.